GLP-1 has been shown to decrease calorie intake in animal models by intracerebroventricular and hypothalamic paraventricular nucleus (PVN) administration.34 An infusion of OXM to normal-weight human subjects produced a reduction in calorie intake of 19.3%, whereas a recent meta-analysis which studied the effect of GLP-1 infusion demonstrated an average reduction in calorie intake of 11.7%
High NNMT exacerbates cell oxidative stress and apoptosis, worsening disease progression
Targeted biologic therapies under evaluation for SLE include anifrolumab, belimumab (intravenous and subcutaneous formulations were registered by FDA for use in SLE in 2017) and off-label rituximab, abatacept, tocilizumab, obintuzumab, and eculizumab.[3] The novel biologic therapy, telitacicept, is currently under investigation
In the obesity drug race, will efficacy alone determine winners, or will tolerability and metabolic benefits become the true differentiators
PMID: 686441 DOI: 10.1097/00000542-197809000-00007 Thatikala A (2025): Pseudocholinesterase Deficiency
It contains the same active ingredient as the Wegovy injection, reduces appetite and slows gastric emptying, and is taken as a once-daily tablet, offering a needle-free alternative to weekly injections
